Memorial Sloan Kettering Cancer Center: Neuroendocrine Tumors trials

The registry lists 14 Neuroendocrine Tumors studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 0 are open to participants now and 5 have results posted.

Early Phase 1 1Phase 1 1Phase 2 6Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus LanreotideCompletedNCT03289741Phase 4Results posted
• A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine TumorsCompletedNCT03070301Phase 2Results posted
• Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine TumorsCompletedNCT02609737Not applicableResults posted
• Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)CompletedNCT01169649Phase 2Results posted
• Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)CompletedNCT00610129Phase 2Results posted
• Defining Response Criteria for PET Scans for People With Neuroendocrine TumorsActive, not recruitingNCT06448208
• Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the LiverActive, not recruitingNCT04544098Early Phase 1
• 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access TrialNo longer availableNCT02358018
• 18F-MFBG Imaging for Evaluation of Neuroendocrine MalignanciesCompletedNCT02348749Phase 1/2
• Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine TumorsCompletedNCT01603004
• The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver MetastasesCompletedNCT01423734
• A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine TumorsCompletedNCT00745381
• Thalidomide in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00027638Phase 2
• Irinotecan in Treating Patients With Advanced Neuroendocrine TumorsCompletedNCT00004922Phase 2